Skip to main content

Table 2 Demographic and clinical characteristics of lymphoma patients with and without VTE

From: Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients

Characteristic Lymphoma patients without VTE Lymphoma patients with VTE p
Age, median (range) 56 (18–87) 54 (19–89) 0.898
Men/women 337/300 37/32 0.900
Hemoglobin, g/L, median (range) 124 (51–172) 117 (87–141) 0.017
Leukocytes, ×109/L, median (range) 7.4 (0.4–28.5) 8.5 (4.6–16.6) 0.132
Platelets, ×109/L, median (range) 248 (29–613) 283 (103–678) 0.034
NLR, median (range) 2.7 (0.2–32.5) 3.79 (0.7–160.5) 0.001
PLR, median (range) 10.1 (0.3–193.3) 14.5 (483.3) 0.001
ESR, mm/h, median (range) 26 (2–150) 38 (2–150) 0.023
CRP, mg/L, median (range) 9.9 (0.1–274.6) 30.6 (0.8–251.8) < 0.001
Fibrinogen, mg/L, median (range) 5.3 (1–13.2) 5.7 (1.9–11.8) 0.351
LDH > reference range limit, n (%) 187 (30.4) 32 (50.8) 0.001
TP < reference range limit, n (%) 258 (40.5) 39 (56.6) 0.024
Albumin < reference range limit, n (%) 70 (11) 15 (21.2) 0.032
B symptomatology, n (%) 360 (56.6) 52 (75.4) 0.001
“Bulky” tumor mass, n (%) 182 (28.5) 34 (49.3) < 0.001
Extranodal localization, n (%) 368 (57.8) 35 (50.7) 0.259
Mediastinal involvement, n (%) 189 (29.6) 32 (46.4) 0.004
IPI > 1, n (%) 153 (52.0) 27 (71.1) 0.027
  1. Legend: VTE venous thromboembolism, min minimum, max maximum, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, ESR erythrocyte sedimentation rate, CRP C-reactive protein, LDH lactate dehydrogenase, TP total proteins, IPI international prognostic index (calculated for DLBCL)